HIF-PH Inhibitors for Anemia in Chronic Kidney Disease: What Are Their Implications in Health-System Pharmacy?

This CPE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by an independent educational grant from AstraZeneca LP in collaboration with Fibrogen.

Release Date

December 22, 2020

Expiration Date

December 21, 2021

Activity Description

In this activity based on a recent live web broadcast, a multidisciplinary panel explores the latest data for HIF-PH inhibitors and examines their efficacy and safety in treating anemia in patients with chronic kidney disease (CKD). The panel also shares evidence-based strategies and describes new models of care for managing patients with CKD-associated anemia, as well as offers practical insight on how clinical pharmacists may take an active role in improving clinical outcomes in patients with CKD.

Target Audience

This activity has been designed to meet the educational needs of clinical pharmacists and other clinicians involved in the management of CKD.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Describe the epidemiology, pathology, and burden of anemia associated with CKD
  • Differentiate the mechanisms of action of current and emerging treatments for anemia associated with CKD
  • Recognize the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia associated with CKD in both nondialysis- and dialysis-dependent patients
  • Apply evidence-based strategies to effectively coordinate with the healthcare team to identify patients with anemia-associated CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

Continuing Pharmacy Education

acpeThe Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Medical Learning Institute, Inc. (MLI) designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: 0468-9999-20-034-H01-P
Type of Activity: Knowledge
Fee Information: There is no fee for this educational activity.

Media: Enduring Material
Time to Complete Activity: 75 minutes

Faculty Disclosures

Steven Fishbane, MD
Chief, Division of Nephrology
Northwell Health
Great Neck, New York

Steven Fishbane, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Akebia Therapeutics, Inc. and AstraZeneca.
Grant/Research Support from Gilead and Megapro.

Wendy L. St. Peter, Pharm.D, FCCP, FNKF, FASN
Professor, College of Pharmacy
University of Minnesota
Minneapolis, Minnesota

Wendy L. St. Peter, Pharm.D, FCCP, FNKF, FASN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Total Renal Care, Inc.
Honoraria from Integritas Health, LLC and Optum, Inc.

Planning Committee Disclosures
Teresa Haile, RPh, MBA, Pharmacy Planner, MLI, has nothing to disclose.

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Margery Tamas, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant for Fresenius Medical Care North America.

Content/Peer Reviewer Disclosures
The following Content/Peer Reviewers have nothing to disclose:

Patricia A. Ensor, RPh, MBA

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For Pharmacists: Upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: mycpemonitor.net.

About This CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.